JPS6341899B2 - - Google Patents
Info
- Publication number
- JPS6341899B2 JPS6341899B2 JP54102128A JP10212879A JPS6341899B2 JP S6341899 B2 JPS6341899 B2 JP S6341899B2 JP 54102128 A JP54102128 A JP 54102128A JP 10212879 A JP10212879 A JP 10212879A JP S6341899 B2 JPS6341899 B2 JP S6341899B2
- Authority
- JP
- Japan
- Prior art keywords
- acid
- hydrochloride
- aminoethyl ester
- compound according
- chloride
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 150000001875 compounds Chemical class 0.000 claims description 22
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 3
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 239000000460 chlorine Substances 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims 1
- JGYPCVMXENEIIE-UHFFFAOYSA-N Cl.NCCOC(=S)C1=CC=C(Cl)C=C1 Chemical compound Cl.NCCOC(=S)C1=CC=C(Cl)C=C1 JGYPCVMXENEIIE-UHFFFAOYSA-N 0.000 claims 1
- GUCJNQQVGFVQJB-UHFFFAOYSA-N Cl.NCCOC(=S)C1=CC=CS1 Chemical compound Cl.NCCOC(=S)C1=CC=CS1 GUCJNQQVGFVQJB-UHFFFAOYSA-N 0.000 claims 1
- OIPBLEAVMUGWDR-UHFFFAOYSA-N O-(2-aminoethyl) 4-methoxybenzenecarbothioate hydrochloride Chemical compound Cl.COC1=CC=C(C(=S)OCCN)C=C1 OIPBLEAVMUGWDR-UHFFFAOYSA-N 0.000 claims 1
- APNAOCORQYFRQO-UHFFFAOYSA-N O-(2-aminoethyl) 4-methylbenzenecarbothioate hydrochloride Chemical compound Cl.CC1=CC=C(C(=S)OCCN)C=C1 APNAOCORQYFRQO-UHFFFAOYSA-N 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 20
- -1 2-aminoethyl ester Chemical class 0.000 description 16
- 239000000243 solution Substances 0.000 description 13
- 239000013078 crystal Substances 0.000 description 12
- 230000000510 mucolytic effect Effects 0.000 description 10
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 8
- 210000002784 stomach Anatomy 0.000 description 8
- OGMADIBCHLQMIP-UHFFFAOYSA-N 2-aminoethanethiol;hydron;chloride Chemical compound Cl.NCCS OGMADIBCHLQMIP-UHFFFAOYSA-N 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 150000001555 benzenes Chemical class 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 238000004949 mass spectrometry Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 210000003097 mucus Anatomy 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- LBVWMBBKFFQMRX-UHFFFAOYSA-N 4-chlorobenzenecarbothioic s-acid Chemical compound SC(=O)C1=CC=C(Cl)C=C1 LBVWMBBKFFQMRX-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- GMEDUXHKSSWXSL-UHFFFAOYSA-N 3-sulfanylpropylazanium;chloride Chemical compound Cl.NCCCS GMEDUXHKSSWXSL-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 239000003172 expectorant agent Substances 0.000 description 3
- 229940066491 mucolytics Drugs 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- JOCRHSHXHVVIFS-UHFFFAOYSA-N thiophene-2-carbothioic s-acid Chemical class SC(=O)C1=CC=CS1 JOCRHSHXHVVIFS-UHFFFAOYSA-N 0.000 description 3
- 229910001868 water Inorganic materials 0.000 description 3
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 2
- YGAPOICUMNPIPF-UHFFFAOYSA-N 4-methoxybenzenecarbothioic s-acid Chemical compound COC1=CC=C(C(S)=O)C=C1 YGAPOICUMNPIPF-UHFFFAOYSA-N 0.000 description 2
- PJHWTWHVCOZCPU-UHFFFAOYSA-N 4-methylbenzenecarbothioic s-acid Chemical compound CC1=CC=C(C(O)=S)C=C1 PJHWTWHVCOZCPU-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 206010037368 Pulmonary congestion Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- MXMOTZIXVICDSD-UHFFFAOYSA-N anisoyl chloride Chemical compound COC1=CC=C(C(Cl)=O)C=C1 MXMOTZIXVICDSD-UHFFFAOYSA-N 0.000 description 2
- UIJGNTRUPZPVNG-UHFFFAOYSA-N benzenecarbothioic s-acid Chemical compound SC(=O)C1=CC=CC=C1 UIJGNTRUPZPVNG-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 239000003517 fume Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000002834 transmittance Methods 0.000 description 2
- 238000001665 trituration Methods 0.000 description 2
- GNETVHIDZPYGGD-UHFFFAOYSA-N 1-aminoethanethiol;hydrochloride Chemical compound Cl.CC(N)S GNETVHIDZPYGGD-UHFFFAOYSA-N 0.000 description 1
- NQKUVVLYLMBAEP-UHFFFAOYSA-N 3,4,5-trimethoxybenzenecarbothioic s-acid Chemical compound COC1=CC(C(S)=O)=CC(OC)=C1OC NQKUVVLYLMBAEP-UHFFFAOYSA-N 0.000 description 1
- BUHYMJLFRZAFBF-UHFFFAOYSA-N 3,4,5-trimethoxybenzoyl chloride Chemical compound COC1=CC(C(Cl)=O)=CC(OC)=C1OC BUHYMJLFRZAFBF-UHFFFAOYSA-N 0.000 description 1
- HMDHOFNCICZZPD-UHFFFAOYSA-N 3,4-dimethylbenzenecarbothioic s-acid Chemical compound CC1=CC=C(C(O)=S)C=C1C HMDHOFNCICZZPD-UHFFFAOYSA-N 0.000 description 1
- RGAKSNQOIIYQRM-UHFFFAOYSA-N 3,4-dimethylbenzoyl chloride Chemical compound CC1=CC=C(C(Cl)=O)C=C1C RGAKSNQOIIYQRM-UHFFFAOYSA-N 0.000 description 1
- OQVKGSDRYMYQKF-UHFFFAOYSA-N 3-(trifluoromethyl)benzenecarbothioic s-acid Chemical compound OC(=S)C1=CC=CC(C(F)(F)F)=C1 OQVKGSDRYMYQKF-UHFFFAOYSA-N 0.000 description 1
- OYEQKMASMPBQMP-UHFFFAOYSA-N 4-carbonochloridoylbenzoic acid Chemical compound OC(=O)C1=CC=C(C(Cl)=O)C=C1 OYEQKMASMPBQMP-UHFFFAOYSA-N 0.000 description 1
- RKIDDEGICSMIJA-UHFFFAOYSA-N 4-chlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(Cl)C=C1 RKIDDEGICSMIJA-UHFFFAOYSA-N 0.000 description 1
- PEQZEAWOMNXGCD-UHFFFAOYSA-N 4-fluorobenzenecarbothioic s-acid Chemical compound FC1=CC=C(C(S)=O)C=C1 PEQZEAWOMNXGCD-UHFFFAOYSA-N 0.000 description 1
- TXTGBKDPANLZJK-UHFFFAOYSA-N 4-sulfanylcarbonylbenzoic acid Chemical compound OC(=O)C1=CC=C(C(O)=S)C=C1 TXTGBKDPANLZJK-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 102000001621 Mucoproteins Human genes 0.000 description 1
- 108010093825 Mucoproteins Proteins 0.000 description 1
- 208000001649 Pica Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 238000010793 Steam injection (oil industry) Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000003434 inspiratory effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L magnesium chloride Substances [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- ZSCGMTWBDWARBZ-UHFFFAOYSA-N o-(2-aminoethyl) benzenecarbothioate;hydrochloride Chemical compound Cl.NCCOC(=S)C1=CC=CC=C1 ZSCGMTWBDWARBZ-UHFFFAOYSA-N 0.000 description 1
- HEPUEHGDWDOZJZ-UHFFFAOYSA-N o-(3-aminopropyl) benzenecarbothioate;hydrochloride Chemical compound Cl.NCCCOC(=S)C1=CC=CC=C1 HEPUEHGDWDOZJZ-UHFFFAOYSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 239000011833 salt mixture Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- QIQITDHWZYEEPA-UHFFFAOYSA-N thiophene-2-carbonyl chloride Chemical compound ClC(=O)C1=CC=CS1 QIQITDHWZYEEPA-UHFFFAOYSA-N 0.000 description 1
- RRKNFMCVKMMBNZ-UHFFFAOYSA-N thiophene-3-carbothioic S-acid Chemical compound SC(=O)C=1C=CSC=1 RRKNFMCVKMMBNZ-UHFFFAOYSA-N 0.000 description 1
- 125000005425 toluyl group Chemical group 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Description
【発明の詳細な説明】
本発明は、粘液溶解活性を有するある種のカル
ボチオ酸−2−アミノアルキルエステルに関し、
とくに肺のうつ血を示す動物における粘液の蓄積
を撲滅および抑制するための置換ベンゼンおよび
2−チオフエン−カルボチオ酸−2−アミノアル
キルエステル酸塩に関する。DETAILED DESCRIPTION OF THE INVENTION The present invention relates to certain carbothioic acid-2-aminoalkyl esters having mucolytic activity;
It relates to substituted benzene and 2-thiophene-carbothioic acid-2-aminoalkyl ester salts for combating and inhibiting mucus accumulation, especially in animals exhibiting pulmonary congestion.
先行技術はベンゼンカルボチオ酸−2−アミノ
エチルエステル塩酸塩を開示している〔W.D.
Foge et al、J.Pharm.Sci51(2)、168−71(1962)〕
が、粘液溶解活性の開示は存在しない。先行技術
はある種の粘液溶解剤、たとえば、遊離のスルフ
ヒドリル基をもつN−アセチル−システインを開
示しているが、本発明の化合物はその基をもたな
い。A.L.Scheffner、Ann.N.Y.Acad.Sci.106、
298−310(1963)は、肺の病気の処置における粘
液溶解剤としてのN−アセチル−L−システイン
の開発において、胃粘素の粘たんぱく質の試験媒
体としての使用を確立した。 The prior art discloses benzenecarbothioic acid-2-aminoethyl ester hydrochloride [WD
Foge et al, J.Pharm.Sci51(2), 168-71 (1962)]
However, there is no disclosure of mucolytic activity. Although the prior art discloses certain mucolytics, such as N-acetyl-cysteine, which has a free sulfhydryl group, the compounds of the present invention do not have that group. ALScheffner, Ann.NYAcad.Sci.106,
298-310 (1963), in the development of N-acetyl-L-cysteine as a mucolytic agent in the treatment of lung diseases, established the use of gastric mucus mucoproteins as a test vehicle.
本発明の化合物は、一般に次の式で表わされる
置換ベンゼンおよび2−チオフエンカルボチオ酸
−2−アミノアルキルエステル酸塩である:
ここでRは2−チエニル基またはハロゲン、低
級アルキル、低級アルコキシ、カルボキシまたは
トリフルオロメチルから選ばれた同一もしくは異
なる1〜3個の基で置換されたフエニル基であ
り、X-は塩素または臭素の基であり、そしてn
は2または3である、
化合物は粘液溶解活性を有し、そして肺のうつ
血を示すかまたはそれに悩まされる温血動物にお
ける粘液を溶解および希釈するのに有用である。 The compounds of the present invention are substituted benzene and 2-thiophenecarbothioic acid-2-aminoalkyl ester salts generally represented by the following formula: Here, R is a 2-thienyl group or a phenyl group substituted with the same or different 1 to 3 groups selected from halogen, lower alkyl, lower alkoxy, carboxy or trifluoromethyl, and X - is chlorine or bromine. and n
is 2 or 3. The compound has mucolytic activity and is useful for dissolving and diluting mucus in warm-blooded animals exhibiting or suffering from pulmonary congestion.
以後記載し、前記式で表わされる化合物は、
以下に記載するようにS.J.Carne et al.J.
Phys.242、116(1974)の方法の変法により、動物
において粘液溶解活性を有することが示された。 The compounds described hereinafter and represented by the above formula are:
As described below, SJCarne et al.
A modification of the method of Phys. 242, 116 (1974) was shown to have mucolytic activity in animals.
粘液溶解活性がラツトの異粘液についてN−ア
セチル−L−システインと同じ程度であることが
わかつた化合物は好ましい化合物であり、それら
は次の通りである。 Compounds whose mucolytic activity was found to be of the same order of magnitude as N-acetyl-L-cysteine for rat heteromucus are preferred compounds, and they are as follows.
(1) 4−クロロベンゼンカルボチオ酸、2−アミ
ノエチルエステル、モノ塩酸塩、
(2) 4−メチルベンゼンカルボチオ酸、2−アミ
ノエチルエステル、モノ塩酸塩、
(3) 4−メトキシベンゼンカルボチオ酸、2−ア
ミノエチルエステル、モノ塩酸塩、
(4) 4−チオフエンカルボチオ酸、2−アミノエ
チルエステル、モノ塩酸塩。(1) 4-chlorobenzenecarbothioic acid, 2-aminoethyl ester, monohydrochloride, (2) 4-methylbenzenecarbothioic acid, 2-aminoethyl ester, monohydrochloride, (3) 4-methoxybenzenecarbothioic acid acid, 2-aminoethyl ester, monohydrochloride, (4) 4-thiophenecarbothioic acid, 2-aminoethyl ester, monohydrochloride.
本発明の化合物の粘液溶解活性を確立するため
に使用する方法は、次の通りである。 The method used to establish the mucolytic activity of compounds of the invention is as follows.
めすのスプラク・ダウレイ(Spraque−
Dawley)(Charles River Labo)120−180gの
ラツトを、1つのかご当り2匹の動物の割合で収
容して、針金上で16時間断食させる。食糞症を最
小にするため、光は断食の間つけたままにしてお
く。2c.c.の水を各ラツトに経口投与して内部の汚
物を最小にする。30分後ラツトを頚部の転位によ
り殺す。胃を取り出し、過剰の組織を切り取り、
上皮部分を廃棄する。胃を薬物溶液中に入れる前
に、小腺部分を大きいわん曲および小さいわん曲
に十分に沿つて切り、胃を外反させる。糞のにお
いをもつか、見える糞物質を含有する胃を廃棄す
る。2.5mg/mlの試驗化合物を含有する10c.c.の溶
液(溶解度に依存して水または50%のポリエチレ
ングリコール300−H2O)中に胃を40分間入れ
る。薬物処理後、胃を10c.c.のアルシアン
(Alcian)ブルー溶液(溶液1)中に90分間入
れ、ここで染料は胃の粘液と錯化する。10c.c.の
0.25モルのスクロース溶液(溶液2)中で2回連
続して10分間洗つた後、胃を10c.c.の0.5モルの
MgCl2溶液(溶液3)中に1時間入れて、錯化し
た染料を除去する。MgCl2の上層を10c.c.のジエチ
ルエーテルと60c.c.の分液漏斗中で振とうして脂質
を除去する。水相をスペクトロニツク
(Spectronic)20管中へ排出し、そして透過率
(%)をスペクトロニツク20分光光度計で605mμ
において読む。透過率を標準曲線からμg/mlの
アルシアンブルーに変換する〔P.Whiteman、
Biochem、J.131、351−57(1973)〕。各薬物また
は薬物の賦形剤(対照)を3つの胃について試驗
する。処理した値と対照の値との間の平均の差を
百分率で表わす。 Female Spraque
(Charles River Labo) Rats weighing 120-180 g are housed at a ratio of 2 animals per cage and fasted for 16 hours on wire. Lights are left on during the fast to minimize coprophagia. Administer 2 c.c. of water orally to each rat to minimize internal waste. After 30 minutes, rats are killed by cervical dislocation. Remove the stomach, cut away excess tissue,
Discard the epithelial portion. Before placing the stomach in the drug solution, cut the glandular section well along the major and minor curvature to evert the stomach. Discard stomachs that smell of feces or contain visible fecal material. The stomach is placed in 10 c.c. of a solution (water or 50% polyethylene glycol 300- H2O depending on solubility) containing 2.5 mg/ml of the test compound for 40 minutes. After drug treatment, the stomach is placed in 10 c.c. of Alcian Blue solution (Solution 1) for 90 minutes, where the dye complexes with the gastric mucus. 10c.c.
After two consecutive 10 minute washes in a 0.25 molar sucrose solution (solution 2), the stomach was washed with 10 c.c.
Place in MgCl 2 solution (solution 3) for 1 hour to remove complexed dye. Remove lipids by shaking the upper layer of MgCl 2 in a 60 c.c. separatory funnel with 10 c.c. diethyl ether. The aqueous phase was drained into a Spectronic 20 tube and the transmittance (%) was measured on a Spectronic 20 spectrophotometer at 605 mμ.
Read in. Convert transmittance from standard curve to Alcian blue in μg/ml [P. Whiteman,
Biochem, J. 131, 351-57 (1973)]. Each drug or drug excipient (control) is tested on three stomachs. The mean difference between treated and control values is expressed as a percentage.
溶液1−アルシアン(Alcian)ブルー、0.05%
W/V(1)
54.8g スクロース(0.15モル)
6.8g 酢酸ナトリウム
900c.c. 脱イオン水
磁気かきまぜ機で溶かし、PH5.8に調整する。
500mgのアルシアンブルー8GN(Matheson
Coleman&Bell#8E13)を加える。メスフラス
コに1を満たす。冷蔵する。1週間だけ使用す
る。Solution 1 - Alcian Blue, 0.05%
W/V (1) 54.8g Sucrose (0.15mol) 6.8g Sodium acetate 900c.c. Deionized water Dissolve with a magnetic stirrer and adjust to PH5.8.
500mg Alcian Blue 8GN (Matheson
Coleman & Bell #8E13). Fill volumetric flask with 1. Refrigerate. Use for only one week.
溶液2−スクロース、0.25モル(1)
85.6gのスクロースを1のメスフラスコに加
える。脱イオン水で体積を満たす。1週間だけ使
用する。Solution 2 - Sucrose, 0.25 moles (1) Add 85.6 g of sucrose to volumetric flask 1. Fill the volume with deionized water. Use for only one week.
溶液3−塩化マグネシウム、0.5モル(1)
101.7gのMgCl2・6H2O ACSを1のメスフ
ラスコに加える。脱イオン水で体積を満たす。Solution 3 - Magnesium Chloride, 0.5 mol (1) Add 101.7 g of MgCl 2 .6H 2 O ACS to 1 volumetric flask. Fill the volume with deionized water.
したがつて本発明の目的は、温血動物における
粘液溶解活性を有する、ある種の新規なカルボチ
オン酸、2−アミノアルキルエステル酸塩を提供
することである。 It is therefore an object of the present invention to provide certain novel carbothionic acid, 2-aminoalkyl ester salts, which have mucolytic activity in warm-blooded animals.
本発明のほかの目的および利点は、本発明を実
施する最良の方法についての以下の説明および特
許請求の範囲から、明らかとなるであろう。 Other objects and advantages of the invention will become apparent from the following description of the best mode of carrying out the invention, and from the claims.
記号の定義および前記式において、そして特
許請求の範囲および明細書のどこかに現われる場
合、用語は次の意味を有する。 In the definitions of symbols and the above formulas, and when appearing elsewhere in the claims and specification, the terms have the following meanings:
ここで使用する「1〜3個の基で置換されたベ
ンゼン」は、Rの定義のもとに上のように定義さ
れた群から選ばれた1〜3個の基で置換されたフ
エニル基を意味し、そしてこれらの置換基はフエ
ニル核の種々の有効な部分に存在することがで
き、そして1より多い置換基が存在するとき、そ
れらは同一であつても異なつていてもよく、互い
に関して種々の位置に存在することができる。低
級アルキルおよび低級アルコキシ置換基のおのお
のは、好ましくは1〜4個の炭素原子を有し、そ
れらは直鎖または分枝鎖として配置できる。好ま
しい置換基の例は、メチル、エチル、プロピル、
ブチル、フルオロ、ブロモ、クロロ、ヨード、メ
トキシ、エトキシ、ブトキシ、カルボキシおよび
トリフルオロメチルである。 As used herein, "benzene substituted with 1 to 3 groups" refers to a phenyl group substituted with 1 to 3 groups selected from the group defined above under the definition of R. and these substituents can be present on various effective parts of the phenyl nucleus, and when more than one substituent is present, they may be the same or different, They can be in various positions with respect to each other. Each of the lower alkyl and lower alkoxy substituents preferably has 1 to 4 carbon atoms and they can be arranged as straight or branched chains. Examples of preferred substituents are methyl, ethyl, propyl,
butyl, fluoro, bromo, chloro, iodo, methoxy, ethoxy, butoxy, carboxy and trifluoromethyl.
置換されたベンゼンおよびチオフエンカルボチ
オ酸、2−アミノアルキルエステル酸塩は、ベン
ゼン誘導体を製造する既知の方法により、次の反
応式で示されるようにして製造される:
ここでR、nおよびX-は上定義したとおりで
ある。 Substituted benzene and thiophenecarbothioic acid, 2-aminoalkyl ester salts are prepared by known methods for preparing benzene derivatives as shown in the following reaction scheme: Here, R, n and X - are as defined above.
一般に、反応成分を混合し、水蒸気噴射の上で
結晶が形成するまで加熱する。次いで結晶を砕
き、リグロインとともに粉砕し、そして無水エタ
ノールから再結晶する。 Generally, the reactants are mixed and heated over a jet of steam until crystals form. The crystals are then crushed, triturated with ligroin, and recrystallized from absolute ethanol.
次の化合物の製造の実施例は本発明を例示する
ことのみを意図し、本発明をいかなる面において
も限定するものと考えてはならない。 The following examples of the preparation of compounds are intended only to illustrate the invention and are not to be considered as limiting the invention in any way.
参考例
ベンゼンカルボチオ酸、2−アミノエチルエス
テル、モノ塩酸塩の合成
15ml(約0.13モル)のベンゾイルクロライドお
よび4.54g(0.04モル)の2−アミノエタンチオ
ール塩酸塩の混合物を、水蒸気噴射の上で2時間
加熱した(湿気から保護した)。わずかに冷却す
ると結晶が生じた。60〜110℃のリグロインとと
もに粉砕し、過し、乾燥した後、結晶は177〜
180℃で溶融した。無水エタノールから数回再結
晶すると、無色の固体、融点178.5〜179.5℃が得
られた。核磁共鳴(NMR)、質量分析(MS)お
よび赤外分析(IR)のすべてにより、ベンゼン
カルボチオ酸、2−アミノエチルエステル、モノ
塩酸塩の構造が確認された。収量は5.1g(59.1
%)であつた。Reference Example Synthesis of benzenecarbothioic acid, 2-aminoethyl ester, monohydrochloride A mixture of 15 ml (approximately 0.13 mol) of benzoyl chloride and 4.54 g (0.04 mol) of 2-aminoethanethiol hydrochloride was heated by steam injection. (protected from moisture) for 2 hours. Crystals formed upon slight cooling. After grinding, filtering and drying with ligroin at 60~110℃, the crystals are 177~
Melted at 180℃. Several recrystallizations from absolute ethanol gave a colorless solid, melting point 178.5-179.5°C. Nuclear magnetic resonance (NMR), mass spectrometry (MS) and infrared analysis (IR) all confirmed the structure of benzenecarbothioic acid, 2-aminoethyl ester, monohydrochloride. The yield is 5.1g (59.1
%).
分析:C9H12ClNOSに対する
計算値:C、49.65;H、5.55;N、6.43
実測値:C、49.58;H、5.59;N、6.49
実施例 1
4−クロロベンゼンカルボチオ酸、2−アミノ
エチルエステル、モノ塩酸塩
60ml(0.47モル)の新らしく蒸留した塩化p−
クロロベンゾイルおよび2−アミノエタンチオー
ル塩酸塩の混合物を、水蒸気噴射の上で2時間加
熱した。反応が完結に向かうにしたがい、固体の
結晶が形成した。注意して温かい60〜110℃のリ
グロインとともに粉砕した後、結晶をリグロイン
で洗いながら過により分離した。無水エタノー
ルから2回再結晶した後、生成物、39.0g(96.5
%)、は208〜209.5℃で溶融した。NMR、MSお
よびIRのすべての分析により、式に従う表題
化合物の構造が確認された。Analysis: Calculated value for C9H12ClNOS : C, 49.65; H, 5.55; N, 6.43 Actual value: C, 49.58; H, 5.59; N, 6.49 Example 1 4-chlorobenzenecarbothioic acid, 2-aminoethyl Ester, monohydrochloride 60 ml (0.47 mol) of freshly distilled p-chloride
A mixture of chlorobenzoyl and 2-aminoethanethiol hydrochloride was heated over a steam jet for 2 hours. As the reaction approached completion, solid crystals formed. After careful trituration with warm 60-110°C ligroin, the crystals were separated by filtration while washing with ligroin. After recrystallization twice from absolute ethanol, the product, 39.0 g (96.5
%), melted at 208-209.5℃. All NMR, MS and IR analyzes confirmed the structure of the title compound according to the formula.
分析:C9H11Cl2SNOについての
計算値:C、42.87;H、4.40;N、5.55
実測値:C、42.79;H、4.43;N、5.59
実施例 2
4−メチルベンゼンカルボチオン酸、2−アミ
ノエチルエステル、モノ塩酸塩
30ml(約0.18モル)の新らしく蒸留した塩化p
−トルオイル、沸点122℃/32mmHgおよび9.68g
(0.085モル)の2−アミノエタンチオール塩酸塩
の混合物を、水蒸気噴射の上で2.25時間加熱した
(湿気から保護した)。反応が完了したとき固体の
結晶が形成した。これを砕き、温かい60〜110℃
のリグロインとともに注意して粉砕し、そして結
晶を過により分離し、温かいリグロインで洗つ
た。無水エタノールから2回再結晶後、生成物、
19.07g(97%)、は206.5〜208℃において溶融し
た。NMR、MSおよびIRのすべての分析により、
式に従う表題化合物の構造が確認された。Analysis: Calculated value for C9H11Cl2SNO : C, 42.87; H, 4.40; N, 5.55 Actual value: C, 42.79; H, 4.43; N, 5.59 Example 2 4 - Methylbenzenecarbothionic acid, 2-Aminoethyl ester, monohydrochloride 30 ml (approximately 0.18 mol) of freshly distilled p chloride
-Toru oil, boiling point 122°C/32mmHg and 9.68g
A mixture of (0.085 mol) of 2-aminoethanethiol hydrochloride was heated over a steam jet (protected from moisture) for 2.25 hours. Solid crystals formed when the reaction was complete. Crush this and warm it to 60-110℃.
of ligroin and the crystals were separated by filtration and washed with warm ligroin. After recrystallizing twice from absolute ethanol, the product,
19.07g (97%) melted at 206.5-208°C. With all NMR, MS and IR analyses,
The structure of the title compound according to the formula was confirmed.
分析:C10H14NOClSに対する
計算値:C、51.83;H、6.09;N、6.04
実測値:C、51.57;H、6.06;N、6.11
実施例 3
4−メトキシベンゼンカルボチオン酸、2−ア
ミノエチルエステル、モノ塩酸塩
23ml(約0.135モル)の塩化p−アニソイルお
よび7.4g(0.065モル)の2−アミノエタンチオ
ール塩酸塩の混合物を、水蒸気噴射の上で約2時
間加熱した(湿気から保護した)。生じた結晶を
砕き、そして温かい60〜110℃のリグロインとと
もに注意して粉砕し、結晶を過により分離し、
そして温かいリグロインで洗つた。無水エタノー
ルから2回結晶後、生成物、14.6g(90.6%)、
は19.15〜193℃で溶融した。NMR、MSおよび
IRのすべての分析により、式に従う表題化合
物の構造が確認された。Analysis: Calculated value for C10H14NOClS : C, 51.83; H, 6.09; N, 6.04 Actual value: C, 51.57; H, 6.06; N, 6.11 Example 3 4-methoxybenzenecarbothionic acid, 2-amino Ethyl ester, monohydrochloride A mixture of 23 ml (about 0.135 mol) of p-anisoyl chloride and 7.4 g (0.065 mol) of 2-aminoethanethiol hydrochloride was heated over a steam jet for about 2 hours (protected from moisture). did). Crush the resulting crystals and carefully grind with warm 60-110°C ligroin, separate the crystals by filtration,
Then I washed it with warm ligroin. After two crystallizations from absolute ethanol, the product, 14.6 g (90.6%),
melted at 19.15-193℃. NMR, MS and
All IR analyzes confirmed the structure of the title compound according to the formula.
分析:C10H14ClNO4Sについての
計算値:C、48.48;H、5.69;N、5.65
実測値:C、48.42;H、5.73;N、5.66
実施例 4
参考例の手順において、塩化ベンゾイルの代わ
りに、等モル量の
3,4,5−トリメトキシベンゾイルクロライ
ド、
4−トリフルオロベンゾイルクロライド、
3−トリフルメチルベンゾイルクロライド、
3,4−ジメチルベンゾイルクロライド、
4−カルボキシベンゾイルクロライド、
を使用すると、
3,4,5−トリメトキシベンゼンカルボチオ
酸、2−アミノエチルエステル、塩酸塩、
4−フルオロベンゼンカルボチオ酸、2−アミ
ノエチルエステル、塩酸塩、
3−トリフルオロメチルベンゼンカルボチオ
酸、2−アミノエチルエステル、塩酸塩、
3,4−ジメチルベンゼンカルボチオ酸、2−
アミノエチルエステル、塩酸塩、
4−カルボキシベンゼンチオ酸、2−アミノエ
チルエステル、塩酸塩、
が得られる。Analysis: Calculated value for C 10 H 14 ClNO 4 S: C, 48.48; H, 5.69; N, 5.65 Actual value: C, 48.42; H, 5.73; N, 5.66 Example 4 In the procedure of the reference example, benzoyl chloride If, instead of, equimolar amounts of 3,4,5-trimethoxybenzoyl chloride, 4-trifluorobenzoyl chloride, 3-triflumethylbenzoyl chloride, 3,4-dimethylbenzoyl chloride, 4-carboxybenzoyl chloride are used , 3,4,5-trimethoxybenzenecarbothioic acid, 2-aminoethyl ester, hydrochloride, 4-fluorobenzenecarbothioic acid, 2-aminoethyl ester, hydrochloride, 3-trifluoromethylbenzenecarbothioic acid, 2-aminoethyl ester, hydrochloride, 3,4-dimethylbenzenecarbothioic acid, 2-
Aminoethyl ester, hydrochloride, 4-carboxybenzenethioic acid, 2-aminoethyl ester, hydrochloride are obtained.
実施例 5
参考例の手順において、2−アミノエタンチオ
ール塩酸の代わりに等モル量の3−アミノプロパ
ンチオール塩酸塩を使用すると、ベンゼンカルボ
チオ酸−3−アミノプロピルエステル塩酸塩が得
られる。Example 5 If an equimolar amount of 3-aminopropanethiol hydrochloride is used in place of 2-aminoethanethiol hydrochloride in the procedure of the reference example, benzenecarbothioic acid-3-aminopropyl ester hydrochloride is obtained.
実施例 6
参考例の手順において、2−アミノエタンチオ
ール塩酸塩の代わりに等モル量の3−アミノプロ
パンチオール塩酸塩を使用し、そして塩化ベンゾ
イルの代わりに、
塩化p−クロロベンゾイル、
塩化p−トルオイル、または
塩化p−アニソイル
を使用すると、
4−クロロベンゼンカルボチオ酸、3−アミノ
プロピルエステル塩酸塩、
4−メチルベンゼンカルボチオ酸、3−アミノ
プロピルエステル塩酸塩、および
4−メトキシベンゼンカルボチオ酸、3−アミ
ノプロピルエステル塩酸塩、
が得られる。Example 6 In the procedure of the reference example, instead of 2-aminoethanethiol hydrochloride, an equimolar amount of 3-aminopropanethiol hydrochloride is used, and instead of benzoyl chloride, p-chlorobenzoyl chloride, p-chloride When using toluoyl, or p-anisoyl chloride, 4-chlorobenzenecarbothioic acid, 3-aminopropyl ester hydrochloride, 4-methylbenzenecarbothioic acid, 3-aminopropyl ester hydrochloride, and 4-methoxybenzenecarbothioic acid , 3-aminopropyl ester hydrochloride, is obtained.
実施例 7
2−チオフエンカルボチオ酸、2−アミノエチ
ルエステル、塩酸塩
15.8g(0.108モル)の新らしく蒸留した塩化
2−チオフエンカルボニルおよび11.3g(0.1モ
ル)の2−アミノエタンチオール塩酸塩の混合物
を、水蒸気噴射の上で6時間加熱した(湿気から
保護した)。生ずる結晶を砕き、そして温かい60
〜110℃のリグロインとともに粉砕し、そして
過して結晶を集めた。無水エタノールから2回再
結晶した後、生成物、8.41g(75.5%)、は195〜
196.5℃で溶融した。NMR、MSおよびIRの分析
のすべてにより、式に従う表題化合物の構造が
確認された。Example 7 2-Thiophenecarbothioic acid, 2-aminoethyl ester, hydrochloride 15.8 g (0.108 mol) freshly distilled 2-thiophenecarbonyl chloride and 11.3 g (0.1 mol) 2-aminoethanethiol hydrochloride The salt mixture was heated over a steam jet for 6 hours (protected from moisture). Crush the resulting crystals and warm 60
Crystals were collected by trituration and straining with ligroin at ~110°C. After recrystallization twice from absolute ethanol, the product, 8.41 g (75.5%), is 195~
It melted at 196.5°C. NMR, MS and IR analyzes all confirmed the structure of the title compound according to the formula.
分析:C7H10ClNOS2についての
計算値:C、37.58;H、4.51;N、6.26
実測値:C、37.68;H、4.50;N、6.30
実施例 8
実施例7の手順において、2−アミノエタンチ
オール塩酸塩の代わりに等モル量の3−アミノプ
ロパンチオール塩酸塩を使用すると、チオフエン
カルボチオ酸、3−アミノプロピルエステル塩酸
塩が得られる。Analysis: Calculated value for C7H10ClNOS2 : C, 37.58; H, 4.51; N, 6.26 Actual value: C, 37.68; H, 4.50; N, 6.30 Example 8 In the procedure of Example 7, 2- When an equimolar amount of 3-aminopropanethiol hydrochloride is used in place of aminoethanethiol hydrochloride, thiophenecarbothioic acid, 3-aminopropyl ester hydrochloride is obtained.
本発明の化合物は、吸入剤として局所的に適用
したとき、ほ乳動物の被検体における肺の滞留に
対して効果的な粘液溶解作用を提供するための製
剤組成物とすることができる。 The compounds of the invention can be formulated into pharmaceutical compositions to provide effective mucolytic action against pulmonary retention in mammalian subjects when applied topically as an inhalant.
式の化合物は、治療を要する温血動物の気道
中の粘液の液化を誘発するために十分な量で投与
される。式の化合物の気道内投与は、種々の吸
入または点滴注入の手段、たとえば、鼻の点滴、
噴霧、煙霧などにより行う。他の適当な投与手段
は、呼吸作用のエネルギーのみを利用するか、あ
るいはエーロゾル噴射剤の使用による、微粒子ま
たは極微粒粉末の注入によるものである。約0.5
〜5重量%の式の粘液溶解剤を含有する溶液ま
たはけん濁液は、噴霧器、煙霧剤、エーロゾルな
どを用いるスプレーによる適用に適当である。 A compound of formula is administered in an amount sufficient to induce liquefaction of mucus in the respiratory tract of a warm-blooded animal in need of treatment. Intra-respiratory administration of compounds of formula can be accomplished by various means of inhalation or instillation, such as nasal instillation,
Perform by spraying, fumes, etc. Other suitable means of administration are by injection of fine particles or very fine powders, using the energy of respiration alone or by the use of aerosol propellants. Approximately 0.5
Solutions or suspensions containing ~5% by weight of mucolytic agents of the formula are suitable for application by spray using nebulizers, fumes, aerosols, and the like.
医学分野における当業者には明らかなように、
特定のほ乳類の被検体に使用すべき化合物の正し
い投与量は、粘液溶解治療を要する状態のひど
さ、ならびに年令、性、体重および被検体の一般
の生理的状態によつて決定される。人間による吸
入のためには、5〜100mgの範囲の個々の投与量
は適当であり、そして粘液溶解のために要求され
るであろう。 As is clear to those skilled in the medical field,
The correct dosage of the compound to be used for a particular mammalian subject will be determined by the severity of the condition requiring mucolytic treatment, as well as the age, sex, weight and general physiological condition of the subject. For inhalation by humans, individual doses in the range 5-100 mg will be appropriate and required for mucolysis.
製剤組成物は、吸入のために適当に分配され
る、散剤中の微粒状化合物の希釈物の形態あるい
は液体中の溶液およびけん濁液の形態を取ること
ができる。 Pharmaceutical compositions can take the form of dilutions of the particulate compound in powders or solutions and suspensions in liquids suitably dispensed for inhalation.
A 吸入装置を用いる投与のための粉末
実施例1の4−クロロベンゼンカルボチオ酸、
2−アミノエチルエステルモノ塩酸塩、微粉砕
物 2.5g
ラクトース粉末 2.5g
粉末を無菌的に配合し、硬質のゼラチンカプ
セルに充てんする。各カプセルは50mgの混合物
を含有する。これは、投与前にカプセル壁を裂
開する手段を有する呼吸で作動される吸入装置
により、吸息の呼吸へ分散するのに適する。A 4-chlorobenzenecarbothioic acid of powder example 1 for administration using an inhalation device;
2-Aminoethyl ester monohydrochloride, finely ground 2.5 g Lactose powder 2.5 g The powders are blended aseptically and filled into hard gelatin capsules. Each capsule contains 50mg of the mixture. It is suitable for dispersion into the inspiratory breath by means of a breath-actuated inhalation device having means for tearing the capsule wall apart before administration.
B 吸入装置を用いる投与のための滅菌溶液
1 活性成分 100mg
2 アルコール95% 1.0c.c.とする量
成分の1および2を加温により溶解し、呼吸
で作動される吸入装置により投与する。B Sterile solution for administration using an inhalation device 1 100 mg of active ingredient 2 Amount to make 1.0 cc of 95% alcohol Ingredients 1 and 2 are dissolved by heating and administered via a breath-actuated inhalation device.
C 水溶液
1 活性成分、実施例1、3または5 10g
2 蒸留水 90g
合計100g
成分1および2を投与形態に希釈し、吸入装
置またはエーロゾルにより投与する。C Aqueous solution 1 Active ingredient, Example 1, 3 or 5 10 g 2 Distilled water 90 g Total 100 g Components 1 and 2 are diluted into a dosage form and administered by inhalation device or aerosol.
Claims (1)
キル、低級アルコキシ、カルボキシまたはトリフ
ルオロメチルから選ばれた同一もしくは異なる1
〜3個の基で置換されたフエニル基であり、X-
は塩素または臭素のイオンであり、そしてnは2
または3である) を有する化合物。 2 4−クロロベンゼンカルボチオ酸2−アミノ
エチルエステルモノ塩酸塩である、特許請求の範
囲第1項記載の化合物。 3 4−メチルベンゼンカルボチオ酸2−アミノ
エチルエステルモノ塩酸塩である、特許請求の範
囲第1項記載の化合物。 4 4−メトキシベンゼンカルボチオ酸2−アミ
ノエチルエステルモノ塩酸塩である、特許請求の
範囲第1項記載の化合物。 5 2−チオフエンカルボチオ酸2−アミノエチ
ルエステルモノ塩酸塩である、特許請求の範囲第
1項記載の化合物。[Claims] 1. General formula: (R is the same or different group selected from 2-thienyl group, halogen, lower alkyl, lower alkoxy, carboxy or trifluoromethyl)
A phenyl group substituted with ~3 groups, X -
is a chlorine or bromine ion, and n is 2
or 3). 2. The compound according to claim 1, which is 4-chlorobenzenecarbothioic acid 2-aminoethyl ester monohydrochloride. 3. The compound according to claim 1, which is 4-methylbenzenecarbothioic acid 2-aminoethyl ester monohydrochloride. 4. The compound according to claim 1, which is 4-methoxybenzenecarbothioic acid 2-aminoethyl ester monohydrochloride. 5. The compound according to claim 1, which is 2-thiophenecarbothioic acid 2-aminoethyl ester monohydrochloride.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US93274778A | 1978-08-10 | 1978-08-10 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS5536486A JPS5536486A (en) | 1980-03-14 |
JPS6341899B2 true JPS6341899B2 (en) | 1988-08-19 |
Family
ID=25462846
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP10212879A Granted JPS5536486A (en) | 1978-08-10 | 1979-08-10 | Benzene and thiopheneecarbothio acid* 22aminoalkylester acid salt |
JP62271595A Granted JPS63119423A (en) | 1978-08-10 | 1987-10-27 | Pharmacological composition comprising benzene and thiophene-carbothio acid and 2-aminoalkylester acid salt |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP62271595A Granted JPS63119423A (en) | 1978-08-10 | 1987-10-27 | Pharmacological composition comprising benzene and thiophene-carbothio acid and 2-aminoalkylester acid salt |
Country Status (17)
Country | Link |
---|---|
JP (2) | JPS5536486A (en) |
AU (1) | AU520791B2 (en) |
BE (1) | BE878169A (en) |
CA (1) | CA1125297A (en) |
CH (1) | CH642062A5 (en) |
DE (1) | DE2932402A1 (en) |
DK (1) | DK159655C (en) |
EG (1) | EG14416A (en) |
ES (1) | ES483269A1 (en) |
FI (1) | FI69060C (en) |
FR (2) | FR2433016A1 (en) |
GB (1) | GB2028325B (en) |
IE (1) | IE48794B1 (en) |
IL (1) | IL57859A (en) |
IT (1) | IT1118828B (en) |
PH (1) | PH16277A (en) |
ZA (1) | ZA794171B (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1170862B (en) * | 1981-03-31 | 1987-06-03 | Sigma Tau Ind Farmaceuti | MERCAPTOACIL-CARNITINE PROCEDURE FOR THEIR PREPARATION AND THERAPEUTIC USE |
JP3635780B2 (en) * | 1996-04-08 | 2005-04-06 | 株式会社デンソー | Honeycomb structure forming apparatus and forming method |
CN110597249B (en) * | 2019-08-23 | 2022-08-05 | 深圳市优必选科技股份有限公司 | Robot and recharging positioning method and device thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3328442A (en) * | 1963-12-18 | 1967-06-27 | Massachusetts College Of Pharm | Anti-radiation compounds and their preparation |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2342142A (en) * | 1937-09-09 | 1944-02-22 | Squibb & Sons Inc | Esters of sulphur-containing benzoic acids and process of preparing them |
DE2335079C3 (en) * | 1973-02-21 | 1979-02-15 | Laboratories Made S.A., Madrid | Aminoalkyl derivatives of 3,5-dimethylbenzoic acid and their salts and processes for their preparation |
IL57881A (en) * | 1978-08-10 | 1982-12-31 | Robins Co Inc A H | Pharmaceutical compositions containing benzamidoalkyl merccaptans |
US4210666A (en) * | 1978-08-10 | 1980-07-01 | A. H. Robins Company, Inc. | Mucolytic thiophenecarboxamido alkyl mercaptans |
-
1979
- 1979-07-20 IL IL57859A patent/IL57859A/en unknown
- 1979-08-03 CH CH716879A patent/CH642062A5/en not_active IP Right Cessation
- 1979-08-03 PH PH22851A patent/PH16277A/en unknown
- 1979-08-08 GB GB7927694A patent/GB2028325B/en not_active Expired
- 1979-08-08 EG EG487/79A patent/EG14416A/en active
- 1979-08-08 IE IE1520/79A patent/IE48794B1/en unknown
- 1979-08-09 IT IT68643/79A patent/IT1118828B/en active
- 1979-08-09 BE BE0/196671A patent/BE878169A/en not_active IP Right Cessation
- 1979-08-09 AU AU49756/79A patent/AU520791B2/en not_active Ceased
- 1979-08-09 FR FR7920412A patent/FR2433016A1/en active Granted
- 1979-08-09 DK DK333879A patent/DK159655C/en not_active IP Right Cessation
- 1979-08-09 DE DE19792932402 patent/DE2932402A1/en active Granted
- 1979-08-09 CA CA333,424A patent/CA1125297A/en not_active Expired
- 1979-08-09 FI FI792474A patent/FI69060C/en not_active IP Right Cessation
- 1979-08-09 ES ES483269A patent/ES483269A1/en not_active Expired
- 1979-08-10 ZA ZA00794171A patent/ZA794171B/en unknown
- 1979-08-10 JP JP10212879A patent/JPS5536486A/en active Granted
-
1980
- 1980-02-14 FR FR8003290A patent/FR2453150A1/en active Granted
-
1987
- 1987-10-27 JP JP62271595A patent/JPS63119423A/en active Granted
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3328442A (en) * | 1963-12-18 | 1967-06-27 | Massachusetts College Of Pharm | Anti-radiation compounds and their preparation |
Also Published As
Publication number | Publication date |
---|---|
ZA794171B (en) | 1980-08-27 |
IE791520L (en) | 1980-02-10 |
AU4975679A (en) | 1980-02-14 |
AU520791B2 (en) | 1982-02-25 |
JPH0262530B2 (en) | 1990-12-26 |
CA1125297A (en) | 1982-06-08 |
JPS63119423A (en) | 1988-05-24 |
JPS5536486A (en) | 1980-03-14 |
DE2932402C2 (en) | 1988-12-22 |
BE878169A (en) | 1979-12-03 |
PH16277A (en) | 1983-08-26 |
GB2028325B (en) | 1982-11-17 |
FR2453150A1 (en) | 1980-10-31 |
DE2932402A1 (en) | 1980-02-21 |
GB2028325A (en) | 1980-03-05 |
IE48794B1 (en) | 1985-05-15 |
FI69060C (en) | 1985-12-10 |
DK333879A (en) | 1980-02-11 |
IT7968643A0 (en) | 1979-08-09 |
DK159655C (en) | 1991-04-08 |
CH642062A5 (en) | 1984-03-30 |
IL57859A0 (en) | 1979-11-30 |
EG14416A (en) | 1984-06-30 |
FI69060B (en) | 1985-08-30 |
DK159655B (en) | 1990-11-12 |
FR2433016A1 (en) | 1980-03-07 |
FI792474A (en) | 1980-02-11 |
IL57859A (en) | 1983-02-23 |
ES483269A1 (en) | 1980-04-16 |
FR2453150B1 (en) | 1983-05-20 |
FR2433016B1 (en) | 1983-05-13 |
IT1118828B (en) | 1986-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK159264B (en) | ANALOGY PROCEDURE FOR PREPARING D- (THREO) -1-ARYL-2-ACYLAMIDO-3-FLUOR-1-PROPANOL COMPOUNDS | |
JPH04257587A (en) | Codein salt of substituted carboxylic acid | |
JP2562475B2 (en) | Novel compounds, medical compositions, and methods of treating inflammation and pain | |
JPH0150698B2 (en) | ||
JPS6341899B2 (en) | ||
US4210666A (en) | Mucolytic thiophenecarboxamido alkyl mercaptans | |
US4296092A (en) | Mucolytic benzene and thiophene-carbothioic acid 2-aminoalkyl ester acid salts | |
CA1134273A (en) | Benzene and thiophene-carbothioic acid 2-aminoalkyl ester acid salts | |
JPS60158149A (en) | Antiinflammatory 1,4-naphthoquinone derivative | |
JPH0314036B2 (en) | ||
JPS6361311B2 (en) | ||
GB2098596A (en) | Benzamidoalkyl mercaptans | |
SE434835B (en) | N- (1-METHYL-2-PYRROLIDINYLMETHYL) -2,3-DIMETOXY-5-METHYLSULPHAMOYL-BENZAMIDE, ITS PREPARATION AND PHARMACOLOGICAL COMPOSITION CONTAINING THIS NEW BENZAMIDE | |
JPS60142968A (en) | Novel diazine-ethenylphenyloxamic acid | |
JPS58116482A (en) | N-(tetrazol-5-yl)phenazine-1-carboxamide | |
JPS5942377A (en) | Dithiol derivative | |
JPH0412267B2 (en) | ||
JPH1045592A (en) | Therapeutic agent for diabetic complication | |
JPH11502519A (en) | Novel 1-ethyl-1,2-dihydro-2-oxo-3-methylaminoquinoxaline derivatives, their use as medicaments, and pharmaceutical compositions containing them | |
JPS6126790B2 (en) | ||
JPS62198684A (en) | 3-(1h-tetrazol-5-yl)thieno(2,3-d)pyrimidine-4(3h)-ones | |
BE878168A (en) | BENZAMIDO-ALKYL-MERCAPTANS MUCOLYTIC MEDICINAL PRODUCTS | |
JPS61200916A (en) | Remedy for hepatopathy | |
JPS63313750A (en) | 2-(2-fluoro-4-biphenylyl)propionic acid ester and anti-inflammatory agent containing said ester as active component | |
HRP940853A2 (en) | Process for the preparation of new thienyloxyactic acid derivatives |